Basic Information
| LncRNA/CircRNA Name | GAS5 |
| Synonyms | GAS5, NCRNA00030, SNHG2, ENST00000456293.5, GAS5-007 |
| Region | GRCh38_1:173863900-173868882 |
| Ensemble | ENSG00000234741 |
| Refseq | NR_002578 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | Trastuzumab | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | breast cancer |
| ICD-0-3 | C50 |
| Methods | Microarray, qPCR etc. |
| Sample | breast cancer tissues, cell line (SKBR-3) |
| Expression Pattern | down-regulated |
| Function Description | Expression of the lncRNA GAS5 was decreased in SKBR-3/Tr cells and in breast cancer tissue from trastuzumab-treated patients. Inhibition of GAS5 promoted SKBR-3 cell proliferation, and GAS5 knockdown partially reversed lapatinib-induced inhibition of SKBR-3/Tr cell proliferation. GAS5 suppresses cancer proliferation by acting as a molecular sponge for miR-21, leading to the de-repression of phosphatase and tensin homologs (PTEN), the endogenous target of miR-21. Moreover, mTOR activation associated with reduced GAS5 expression was required to suppress PTEN. |
| Pubmed ID | 27034004 |
| Year | 2016 |
| Title | Downregulation of LncRNA GAS5 causes trastuzumab resistance in breast cancer |
External Links
| Links for GAS5 | GenBank HGNC NONCODE |
| Links for breast cancer | OMIM COSMIC |